Web: | mayocliniclabs.com |
---|---|
Email: | mcl@mayo.edu |
Telephone: | 800-533-1710 |
International: | +1 855-379-3115 |
Values are valid only on day of printing. |
Providing a genetic evaluation for patients with a personal or family history suggestive of Brugada syndrome (BrS)
Establishing a diagnosis of a BrS, in some cases, allowing for appropriate management and surveillance for disease features based on the gene involved
Identifying variants within genes known to be associated with increased risk for disease features and allowing for predictive testing of at-risk family members
This test includes next-generation sequencing and supplemental Sanger sequencing to evaluate the genes tested on this panel.
Prior Authorization is available for this assay; see Special Instructions.
This test uses next generation sequencing to test for variants in the CACNA1C, CACNA2D1, GPD1L, KCNE3, KCNJ8, SCN3B, CACNB2, SCN1B, and SCN5A genes.
This test may aid in the diagnosis of Brugada syndrome.
Identification of a pathogenic variant may assist with prognosis, clinical management, familial screening, and genetic counseling.
Custom Sequence Capture and Targeted Next Generation Sequencing Followed by Polymerase Chain Reaction (PCR) and Supplemental Sanger Sequencing